Tofacitinib and newer JAK inhibitors in inflammatory bowel disease—where we are and where we are going

Inflammatory bowel diseases, comprising ulcerative colitis (UC) and Crohn’s disease, are chronic, immune-mediated and progressive inflammatory disorders affecting the gastrointestinal tract. Tofacitinib is the first oral small-molecule Janus kinase (JAK) inhibitor licensed and approved by the Nation...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Eleanor, Aslam, Nasar, Nigam, Gaurav, Limdi, Jimmy K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9007061/
https://www.ncbi.nlm.nih.gov/pubmed/35462642
http://dx.doi.org/10.7573/dic.2021-11-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9007061/
https://www.ncbi.nlm.nih.gov/pubmed/35462642
http://dx.doi.org/10.7573/dic.2021-11-4

Ejemplares similares